Bracanat 100mg Tablet

Bracanat 100mg tablet is a prescription based medication. Doctor prescribed this medication for breast and ovarian cancer. Its active ingredient is Olaparib and belongs to PARP inhibitor. These medications work by blocking the PARP enzyme which help repair damaged DNA in cancer cells, leading to cancer cell death and slow the progression of the disease in the body. The medication should be prescribed alone or in combination of other medications. Doctor prescription is essential to ensure safe and effective treatment.

Ovarian and breast cancer

Every medication has several side effects, some may resolve on their own and some need proper medical attention to cure the symptoms. Consult the doctor if any of these symptoms persist:
● Muscle cramps
● Confusion, visual disturbances, seizures, and headache
● Breathlessness
● Swelling of feet
● Changes in heartbeat
● High blood pressure
● Pneumonia
● Loss of appetite
● Sensitivity, tingling and burning sensation of the skin
● Nausea, vomiting, and diarrhea
● Mouth ulcers
● Constipation

Bracanat 100mg tablet should be taken with or without food. Swallow it with whole glass of water. Do not miss or overdose the medication as it may affect the treatment outcomes. Consult the doctor but do not self administer or change the dose on your own. Taking it in the wrong way may cause serious side effects and interfere with the effectiveness of the treatment.

Bracanat 100mg tablet is a targeted therapy. It contains PARP inhibitor a drug belongs to the class of anti-cancer agents which is designed to block the PARP enzyme that is responsible for repairing DNA in cancer cells. By blocking the enzyme, medicine slows down the progression of cancer cells in the body and protects the body from further growing cancer in the body.

• Bochum, S., Berger, S., & Martens, U. M. (2018). Olaparib. Small molecules in oncology, 217-233.
• Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R., ... & Harter, P. (2019). Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New England Journal of Medicine, 381(25), 2416-2428.
• Goulooze, S. C., Cohen, A. F., & Rissmann, R. (2016). Olaparib. British journal of clinical pharmacology, 81(1), 171-173.
• Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., ... & de Bono, J. (2020). Survival with olaparib in metastatic castration-resistant prostate cancer. New England Journal of Medicine, 383(24), 2345-2357.
• Moore, K., Colombo, N., Scambia, G., Kim, B. G., Oaknin, A., Friedlander, M., ... & DiSilvestro, P. (2018). Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine, 379(26), 2495-2505.